EP0590060B1
(en)
*
|
1991-06-21 |
1997-09-17 |
University Of Cincinnati |
Orally administrable therapeutic proteins and method of making
|
US6613332B1
(en)
|
1991-06-21 |
2003-09-02 |
The University Of Cincinnati |
Oral administration of therapeutic proteins
|
US6083503A
(en)
*
|
1991-08-28 |
2000-07-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection
|
ES2095001T5
(es)
†
|
1992-12-22 |
2001-03-16 |
Univ Cincinnati |
Una composicion terapeutica administrable oralmente y su metodo de obtencion.
|
US5744155A
(en)
*
|
1993-08-13 |
1998-04-28 |
Friedman; Doron |
Bioadhesive emulsion preparations for enhanced drug delivery
|
US5514670A
(en)
*
|
1993-08-13 |
1996-05-07 |
Pharmos Corporation |
Submicron emulsions for delivery of peptides
|
US5551058A
(en)
*
|
1994-10-31 |
1996-08-27 |
Motorola, Inc. |
Method and system for intelligent cell selection using location data in cellular systems
|
US20040018236A1
(en)
*
|
1995-05-08 |
2004-01-29 |
Robert Gurny |
Nanoparticles for oral administration of pharmaceutical agents of low solubility
|
US6605276B1
(en)
*
|
1995-05-09 |
2003-08-12 |
University Of Medicine & Dentistry Of New Jersey |
Treatment of ulcerative colitis with tropomyosin isoforms and monoclonal antibodies to tropomyosin isoforms
|
US5789014A
(en)
*
|
1995-12-25 |
1998-08-04 |
Shin-Etsu Chemical Co., Ltd. |
Method of manufacturing a solid preparation coated with non-solvent coating
|
JP2000509146A
(ja)
*
|
1996-04-12 |
2000-07-18 |
オンコール,インコーポレーテッド |
遅延クエンチングによりホルムアルデヒド固定を制御する方法および組成物
|
US6274591B1
(en)
|
1997-11-03 |
2001-08-14 |
Joseph F. Foss |
Use of methylnaltrexone and related compounds
|
US20030158220A1
(en)
*
|
1997-11-03 |
2003-08-21 |
Foss Joseph F. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
|
US6559158B1
(en)
|
1997-11-03 |
2003-05-06 |
Ur Labs, Inc. |
Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
|
US6328967B1
(en)
*
|
1998-03-12 |
2001-12-11 |
Allergenics, Inc. |
Delivery system to modulate immune response
|
IL126447A
(en)
*
|
1998-10-04 |
2004-09-27 |
Vascular Biogenics Ltd |
An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
|
DE19854749A1
(de)
*
|
1998-11-27 |
2000-05-31 |
Privates Inst Bioserv Gmbh |
Verwendung von Kapseln, die eine oder mehrere antigene Substanzen enthalten, zur Prävention und/oder Behandlung von Autoimmunerkrankungen
|
CA2354183A1
(en)
*
|
1998-11-30 |
2000-06-08 |
Cytos Biotechnology Ag |
Ordered molecular presentation of antigens, method of preparation and use
|
US6432448B1
(en)
*
|
1999-02-08 |
2002-08-13 |
Fmc Corporation |
Edible coating composition
|
AU1267501A
(en)
*
|
1999-09-07 |
2001-04-10 |
Bioserv Ag |
Novel autogenous vaccines used to obtain an immune tolerance
|
US6500462B1
(en)
*
|
1999-10-29 |
2002-12-31 |
Fmc Corporation |
Edible MCC/PGA coating composition
|
AU783099B2
(en)
*
|
2000-01-07 |
2005-09-22 |
Rohm Gmbh & Co. Kg |
Selective activation of a TH1 or TH2 lymphocyte regulated immune response
|
US7780967B2
(en)
*
|
2000-02-08 |
2010-08-24 |
Allergan, Inc. |
Reduced toxicity Clostridial toxin pharmaceutical compositions
|
US20030118598A1
(en)
*
|
2000-02-08 |
2003-06-26 |
Allergan, Inc. |
Clostridial toxin pharmaceutical compositions
|
US20060269575A1
(en)
*
|
2000-02-08 |
2006-11-30 |
Allergan, Inc. |
Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
|
BR0108173A
(pt)
*
|
2000-02-08 |
2003-01-21 |
Allergan Inc |
Composições farmacêuticas de toxina de botulina
|
US8632785B2
(en)
*
|
2000-02-08 |
2014-01-21 |
Allergan, Inc. |
Clostridial toxin pharmaceutical composition containing a gelatin fragment
|
WO2002038609A2
(en)
|
2000-11-10 |
2002-05-16 |
Proteopharma Aps |
Apolipoprotein conjugates
|
TR200300731T2
(tr)
|
2000-11-28 |
2004-08-23 |
Fmc Corporation |
Yenebilir PGA kaplama bileşimi
|
US6932861B2
(en)
*
|
2000-11-28 |
2005-08-23 |
Fmc Corporation |
Edible PGA coating composition
|
US20060040899A1
(en)
*
|
2000-12-15 |
2006-02-23 |
Hassan Jomaa |
Medicaments containing bisphosphonic acids and derivatives thereof for preventing and treating diseases and allergies
|
DE60234183D1
(de)
*
|
2001-06-05 |
2009-12-10 |
Univ Chicago |
Verwendung von methylnaltrexon zur behandlung von immunsuppression
|
US20030083286A1
(en)
*
|
2001-08-22 |
2003-05-01 |
Ching-Leou Teng |
Bioadhesive compositions and methods for enhanced intestinal drug absorption
|
US20030124196A1
(en)
*
|
2001-08-22 |
2003-07-03 |
Susan Weinbach |
Pulsatile release compositions and methods for enhanced intestinal drug absorption
|
EP1463527A4
(en)
*
|
2001-10-04 |
2005-05-11 |
Protein Therapeutics Inc |
USE OF GAMMAGLOBULIN FOR THE TREATMENT OF IMMUNE-MEDIATED DISEASES
|
KR20040047915A
(ko)
*
|
2001-10-15 |
2004-06-05 |
룀 게엠베하 운트 콤파니 카게 |
활성제로서 펩타이드 또는 단백질을 함유하는 생약 형태를제조하기 위한 공중합체의 용도
|
CN100467060C
(zh)
|
2002-05-10 |
2009-03-11 |
阿根尼克斯有限公司 |
通过瘤内施用乳铁蛋白治疗恶性肿瘤疾病的用途
|
US20040043070A1
(en)
*
|
2002-05-14 |
2004-03-04 |
Ayres James W. |
Hot melt coating by direct blending and coated substrates
|
US7977098B2
(en)
|
2002-05-31 |
2011-07-12 |
Children's Hospital Medical Center |
Antigenic binding patterns of norovirus to human histo-blood group antigens
|
EP1532279B1
(en)
*
|
2002-05-31 |
2011-02-16 |
Children's Hospital Medical Center |
Method, composition and kit for antigenic binding of norwalk-like viruses
|
DK1545587T3
(da)
|
2002-09-16 |
2011-05-09 |
Agennix Inc |
Lactoferrinsammensætninger og fremgangsmåder til behandling af diabetiske sår
|
DE60336406D1
(de)
|
2002-10-16 |
2011-04-28 |
Purdue Pharma Lp |
Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
|
BRPI0316092B8
(pt)
|
2002-11-08 |
2021-05-25 |
Ablynx Nv |
anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos
|
NZ563471A
(en)
|
2002-11-08 |
2009-04-30 |
Ablynx Nv |
Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
|
AU2004204262B2
(en)
|
2003-01-10 |
2010-11-04 |
Ablynx N.V. |
Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen
|
MXPA05010817A
(es)
*
|
2003-04-08 |
2006-03-30 |
Progenics Pharm Inc |
Formulaciones farmaceuticas que contienen metilnaltrexona.
|
RU2373936C2
(ru)
*
|
2003-04-08 |
2009-11-27 |
Проджиникс Фармасьютикалз, Инк. |
Применение метилналтрексона для лечения синдрома раздраженного кишечника
|
CN1767855A
(zh)
*
|
2003-04-08 |
2006-05-03 |
普罗热尼奇制药公司 |
包含缓泻剂和外周阿片拮抗剂的便秘的组合疗法
|
US20070141071A1
(en)
*
|
2003-05-14 |
2007-06-21 |
Oregon State University |
Hot melt coating by direct blending and coated substrates
|
US9050352B2
(en)
*
|
2003-10-16 |
2015-06-09 |
Stephen John Ralph |
Immunomodulating compositions and uses therefor
|
DK1687338T3
(da)
|
2003-11-07 |
2011-02-07 |
Ablynx Nv |
Camelidae enkeltdomæne-antistoffer VHH, der er rettet mod epidermal vækstfaktor-receptor og anvendelser deraf
|
AU2005290238A1
(en)
|
2004-09-18 |
2006-04-06 |
Department Of Veterans Affairs |
Therapeutic agents trageting the NCCa-ATP channel and methods of use thereof
|
KR20070084170A
(ko)
*
|
2004-10-13 |
2007-08-24 |
아블린쓰 엔.브이. |
알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드
|
WO2006078842A1
(en)
*
|
2005-01-20 |
2006-07-27 |
Progenics Pharmaceuticals, Inc. |
Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
|
US9662325B2
(en)
|
2005-03-07 |
2017-05-30 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
US8524731B2
(en)
*
|
2005-03-07 |
2013-09-03 |
The University Of Chicago |
Use of opioid antagonists to attenuate endothelial cell proliferation and migration
|
US8518962B2
(en)
|
2005-03-07 |
2013-08-27 |
The University Of Chicago |
Use of opioid antagonists
|
ES2714198T3
(es)
*
|
2005-03-07 |
2019-05-27 |
Univ Chicago |
Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
|
US20090226367A1
(en)
*
|
2005-03-11 |
2009-09-10 |
Euro-Celtique S.A. |
Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
|
JP5749881B2
(ja)
|
2005-04-22 |
2015-07-15 |
ユニヴェルシテ デ ジュネーブ |
ポリラクチド組成物およびその使用
|
US7964200B2
(en)
|
2005-05-18 |
2011-06-21 |
Children's Hospital & Research Center At Oakland |
Methods and compositions for immunizing against Chlamydia infection
|
EP2949668B1
(en)
|
2005-05-18 |
2019-08-14 |
Ablynx N.V. |
Improved nanobodies tm against tumor necrosis factor-alpha
|
RU2433139C2
(ru)
|
2005-05-20 |
2011-11-10 |
Аблинкс Н.В. |
Nanobodies tm для лечения заболеваний, опосредованных агрегацией
|
AR057325A1
(es)
*
|
2005-05-25 |
2007-11-28 |
Progenics Pharm Inc |
Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
|
AR057035A1
(es)
*
|
2005-05-25 |
2007-11-14 |
Progenics Pharm Inc |
SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
|
US20080194611A1
(en)
*
|
2005-06-03 |
2008-08-14 |
Alverdy John C |
Modulation of Cell Barrier Dysfunction
|
CA2655331A1
(en)
|
2006-06-22 |
2007-12-27 |
Agennix Incorporated |
Lactoferrin as a radioprotective agent
|
TW200817048A
(en)
*
|
2006-09-08 |
2008-04-16 |
Wyeth Corp |
Dry powder compound formulations and uses thereof
|
US20110152263A1
(en)
*
|
2006-11-16 |
2011-06-23 |
Xi Jiang |
Composition and method for inhibiting norovirus infection
|
US9511075B2
(en)
|
2007-01-12 |
2016-12-06 |
The University Of Maryland, Baltimore |
Targeting NCCA-ATP channel for organ protection following ischemic episode
|
WO2008097835A2
(en)
|
2007-02-02 |
2008-08-14 |
Baylor College Of Medicine |
Compositions and methods for the treatment of metabolic disorders
|
PT2139890E
(pt)
*
|
2007-03-29 |
2014-09-03 |
Wyeth Llc |
Antagonistas do receptor opióide periférico e respectivas utilizações
|
US20100305323A1
(en)
|
2007-03-29 |
2010-12-02 |
Smolenskaya Valeriya N |
Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
|
JP5461386B2
(ja)
|
2007-03-29 |
2014-04-02 |
プロジェニックス ファーマシューティカルズ,インコーポレーテッド |
末梢オピオイド受容体アンタゴニストおよびその使用
|
MX2009013004A
(es)
|
2007-06-01 |
2010-01-20 |
Univ Maryland |
Agentes de union al receptor de la region constante fc de inmunoglobulina.
|
JP5322405B2
(ja)
*
|
2007-06-07 |
2013-10-23 |
小林製薬株式会社 |
タンパク質含有組成物
|
EP2167107B1
(en)
|
2007-06-22 |
2016-12-14 |
University of Maryland, Baltimore |
Inhibitors of ncca-atp channels for therapy
|
EP2240489A1
(en)
|
2008-02-06 |
2010-10-20 |
Progenics Pharmaceuticals, Inc. |
Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
|
AU2009225434B2
(en)
*
|
2008-03-21 |
2014-05-22 |
The University Of Chicago |
Treatment with opioid antagonists and mTOR inhibitors
|
CA2729582C
(en)
|
2008-07-01 |
2017-09-19 |
University Of Chicago |
Particles containing an opioid receptor antagonist and methods of use
|
EP2719380A3
(en)
|
2008-09-16 |
2014-07-30 |
University of Maryland, Baltimore |
SUR1 inhibitors for therapy
|
CA2676881C
(en)
|
2008-09-30 |
2017-04-25 |
Wyeth |
Peripheral opioid receptor antagonists and uses thereof
|
US8765817B1
(en)
|
2008-12-03 |
2014-07-01 |
Arrowhead Center, Inc. |
Selective inhibitors of EG5 motors and methods of use
|
US8349899B1
(en)
|
2008-12-03 |
2013-01-08 |
Arrowhead Center, Inc. |
Selective inhibitors of EG5 motors and methods of use
|
WO2010124276A2
(en)
|
2009-04-24 |
2010-10-28 |
Vanderbilt Universtiy |
Anti-tgf-beta induction of bone cell function and bone growth
|
CN102612525A
(zh)
|
2009-06-09 |
2012-07-25 |
儿童医院医疗中心 |
抗原-诺罗病毒p-结构域单体和二聚体,抗原-诺罗病毒p-粒子分子,及其制备和应用方法
|
EP3100610A1
(en)
|
2009-07-24 |
2016-12-07 |
Baylor College Of Medicine |
Methods of modulation of branched chain acids and uses thereof
|
JP2013520475A
(ja)
|
2010-02-25 |
2013-06-06 |
アゲンニックス・アーゲー |
重症敗血症の治療における経口ラクトフェリン
|
BR112013002074B1
(pt)
|
2010-07-28 |
2021-09-14 |
Gliknik Inc |
Composto homodimérico, dímero ou multímero de ordem superior do composto homodimérico, composição, composto, multímero e usos dos mesmos
|
EP2606152B1
(en)
|
2010-08-18 |
2016-10-05 |
Fred Hutchinson Cancer Research Center |
Methods for determining the presence or risk of developing facioscapulohumeral dystrophy (fshd)
|
US11246915B2
(en)
|
2010-09-15 |
2022-02-15 |
Applied Molecular Transport Inc. |
Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
|
BR112013006088B1
(pt)
|
2010-09-15 |
2022-06-14 |
Randall J Mrsny |
Construto de entrega isolado, e, composição farmacêutica
|
EP2629782B1
(en)
|
2010-10-18 |
2019-02-20 |
Agency For Science, Technology And Research |
Use of exosomes derived from mesenchymal stem cells to promote or enhance hair growth
|
WO2012070971A1
(ru)
*
|
2010-11-22 |
2012-05-31 |
Farber Boris Slavinovich |
Косметологическая и фармацевтическая композиция для омоложения и восстанов- ления кожи, в том числе после хирургических операций
|
US9399053B2
(en)
|
2011-07-22 |
2016-07-26 |
The University Of Chicago |
Treatments for migraine and related disorders
|
US9655905B2
(en)
|
2011-09-14 |
2017-05-23 |
King Abdullah University Of Science And Technology |
Treatment of sickle cell disease
|
WO2013041969A2
(en)
|
2011-09-21 |
2013-03-28 |
King Abdullah University Of Science And Technology |
Didemnin biosynthetic gene cluster in tistrella mobilis
|
AR092821A1
(es)
|
2012-04-20 |
2015-05-06 |
Sucampo Ag |
Conjugado de derivado de acido graso-polimero
|
WO2014160339A1
(en)
|
2013-03-13 |
2014-10-02 |
Board Of Regents, The University Of Texas System |
Compounds for treating inflammatory and hyperproliferative diseases
|
US9321803B2
(en)
|
2013-07-12 |
2016-04-26 |
Children's Hospital Medical Center |
Compositions and methods for inhibiting norovirus infection
|
CN105899528B
(zh)
|
2013-12-02 |
2020-09-01 |
贝勒医学院 |
用于维持最佳体重和血糖的新的多肽激素的鉴定
|
CN106255508B
(zh)
*
|
2014-02-20 |
2020-07-07 |
瓦克萨特公司 |
用于小肠递送的制剂
|
CN106460050A
(zh)
*
|
2014-04-28 |
2017-02-22 |
西格马-奥尔德里奇有限责任公司 |
使用靶向核酸内切酶进行哺乳动物基因组的表观遗传修饰
|
IL285716B
(en)
|
2014-05-07 |
2022-09-01 |
Applied Molecular Transp Llc |
Compacted molecules derived from colic toxin for oral delivery of biologically active cargo
|
WO2016025202A1
(en)
|
2014-08-14 |
2016-02-18 |
The Regents Of The University Of Colorado |
Antibody-sirna conjugates and uses therefor
|
EP3191131A4
(en)
|
2014-08-21 |
2018-09-05 |
The General Hospital Corporation |
Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
|
EP3718404A1
(en)
|
2014-10-17 |
2020-10-07 |
Salix Pharmaceuticals, Inc. |
Use of methylnaltrexone to attenuate tumor progession
|
WO2016073184A1
(en)
|
2014-11-04 |
2016-05-12 |
Dana Farber Cancer Institute, Inc. |
Compositions and methods for treating multiple myeloma
|
KR101708200B1
(ko)
|
2015-03-24 |
2017-03-08 |
아우토리브 디벨롭먼트 아베 |
차량용 커튼 에어백
|
WO2016172026A1
(en)
|
2015-04-20 |
2016-10-27 |
The Board Of Regents Of The University Of Texas System |
Clec11a is a bone growth agent
|
EP3791859A1
(en)
*
|
2015-06-12 |
2021-03-17 |
Vaxart, Inc. |
Formulations for small intestinal delivery of rsv and norovirus antigens
|
US10962551B2
(en)
|
2015-06-17 |
2021-03-30 |
The Johns Hopkins University |
TDP-43 in degenerative disease
|
IL256879B1
(en)
|
2015-07-24 |
2024-01-01 |
Gliknik Inc |
Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin FC preparations with enhanced complement binding
|
IL294679B2
(en)
|
2015-08-07 |
2023-10-01 |
Alx Oncology Inc |
Structures with a SIRP-alpha site or its variant
|
EA034582B1
(ru)
|
2015-08-07 |
2020-02-21 |
АЭлЭкс ОНКОЛОДЖИ ИНК. |
Конструкции варианта sirp-альфа и их применение
|
US10695322B2
(en)
|
2016-01-29 |
2020-06-30 |
The Johns Hopkins University |
Inhibitors of bacterial growth
|
US11040025B2
(en)
|
2016-02-17 |
2021-06-22 |
The Johns Hopkins University |
Oxazolidinone for treatment of infections with Mycobacterium tuberculosis
|
WO2017147370A1
(en)
|
2016-02-24 |
2017-08-31 |
The Johns Hopkins University |
Novel antiviral proteins and their uses in therapeutic methods
|
US10888549B2
(en)
|
2016-03-07 |
2021-01-12 |
The Johns Hopkins University |
Pharmaceutical agents targeting cancer stem cells
|
AU2017230792B2
(en)
|
2016-03-10 |
2023-08-10 |
The Johns Hopkins University |
Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
|
US11965009B2
(en)
|
2016-03-10 |
2024-04-23 |
The Johns Hopkins University |
Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
|
US11203626B2
(en)
|
2016-03-10 |
2021-12-21 |
The Johns Hopkins University |
Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
|
KR20230038214A
(ko)
|
2016-03-17 |
2023-03-17 |
더 존스 홉킨스 유니버시티 |
Paris의 파네실화에 의해 파킨슨병을 예방 또는 치료하기 위한 방법
|
WO2017173055A1
(en)
|
2016-03-30 |
2017-10-05 |
The Johns Hopkins University |
Olfr90 specificity and methods of detection
|
AU2017240190A1
(en)
|
2016-03-31 |
2018-09-20 |
Sorriso Pharmaceuticals, Inc. |
Compositions
|
WO2017189483A1
(en)
|
2016-04-25 |
2017-11-02 |
The Johns Hopkins University |
Znt8 assays for drug development and pharmaceutical compositions
|
KR20190032392A
(ko)
|
2016-07-22 |
2019-03-27 |
글리크닉 인코포레이티드 |
향상된 fc 수용체 결합을 갖는 규칙적으로 다량체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
|
EP3295956A1
(en)
|
2016-09-20 |
2018-03-21 |
Biomay Ag |
Polypeptide construct comprising fragments of allergens
|
US11149275B2
(en)
|
2016-10-10 |
2021-10-19 |
The Johns Hopkins University |
Device and method to treat esophageal disorders
|
US11491114B2
(en)
|
2016-10-12 |
2022-11-08 |
Curioralrx, Llc |
Formulations for enteric delivery of therapeutic agents
|
PE20191354A1
(es)
|
2016-12-09 |
2019-10-01 |
Gliknik Inc |
Optimizacion de fabricacion de gl-2045, un stradomer multimerizante
|
US10434089B2
(en)
|
2017-01-25 |
2019-10-08 |
The Johns Hopkins University |
Avibactam and carbapenems antibacterial agents
|
JP2020515531A
(ja)
|
2017-03-28 |
2020-05-28 |
チルドレンズ ホスピタル メディカル センター |
ノロウイルスs粒子ベースのワクチンならびにその作製および使用方法
|
US11892457B2
(en)
|
2017-07-12 |
2024-02-06 |
The Johns Hopkins University |
Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
|
ES2938609T3
(es)
|
2017-09-20 |
2023-04-13 |
Tillotts Pharma Ag |
Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión
|
WO2019118527A1
(en)
|
2017-12-14 |
2019-06-20 |
The Johns Hopkins University |
Novel anti-fungal inhibitors
|
EP4316586A2
(en)
|
2018-03-08 |
2024-02-07 |
Applied Molecular Transport Inc. |
Toxin-derived delivery constructs for oral delivery
|
PT3762009T
(pt)
|
2018-03-08 |
2022-08-22 |
Applied Molecular Transport Inc |
Construções de administração derivadas de toxinas para administração oral
|
EP3921029A4
(en)
|
2019-02-07 |
2022-12-07 |
Baylor College of Medicine |
PERIOSTEAL SKELETAL STEM CELLS IN BONE REPAIR
|
US11717506B2
(en)
|
2019-05-07 |
2023-08-08 |
The Johns Hopkins University |
Neuroprotective compounds for amyotrophic lateral sclerosis
|
CA3141130A1
(en)
|
2019-05-31 |
2020-12-03 |
ALX Oncology Inc. |
Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
|
AU2020294980A1
(en)
|
2019-06-21 |
2022-02-17 |
Sorriso Pharmaceuticals, Inc. |
Polypeptides
|
JP2022538083A
(ja)
|
2019-06-21 |
2022-08-31 |
ソリッソ ファーマシューティカルズ,インク. |
ポリペプチド
|
BR112022002962A2
(pt)
|
2019-08-16 |
2022-07-05 |
Applied Molecular Transport Inc |
Composições, formulações e produção e purificação de interleucina
|